Table 3.
Reasons for anakinra withdrawal
| Disease | No. withdrawals/treated patients | Inefficacy or loss of efficacy | Adverse event | Persistent remission | On-demand treatment | Patient request | Switch to canakinumab |
|---|---|---|---|---|---|---|---|
| AOSD | 20/35 | 14 | 3 | 1 | 0 | 2 | 2 |
| Gout | 18/28 | 0 | 0 | 17 | 1 | 0 | 0 |
| SJIA | 16/26 | 7 | 3 | 5 | 0 | 1 | 6 |
| CAPS | 11/21 | 1 | 1 | 1 | 0 | 8 | 3 |
| MKD | 7/10 | 2 | 2 | 0 | 0 | 3 | 4 |
| FMF | 6/13 | 1 | 3 | 0 | 1 | 1 | 3 |
| SAPHO | 7/9 | 5 | 2 | 0 | 0 | 0 | 0 |
| Schnitzler’s syndrome | 3/7 | 1 | 2 | 0 | 0 | 0 | 1 |
| Spondylo arthritis | 5/5 | 2 | 3 | 0 | 0 | 0 | 0 |
| Vasculitis | 2/4 | 2 | 0 | 0 | 0 | 0 | 2 |
| Chondro calcinosis | 2/4 | 1 | 0 | 1 | 0 | 0 | 0 |
| TRAPS | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
| GPP | 2/3 | 1 | 0 | 1 | 0 | 0 | 0 |
| Polychondritis | 1/3 | 1 | 0 | 0 | 0 | 0 | 0 |
| NAPS12 | 2/2 | 2 | 0 | 0 | 0 | 0 | 0 |
AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome, FMF: familial Mediterranean fever, MKD: mevalonate kinase deficiency, Vasculitis: giant cell arteritis (2) and polyarteritis nodosa (2), GPP: generalized pustular psoriasis, TRAPS: tumor necrosis factor receptor-associated periodic syndrome, NAPS 12: NLRP12-associated periodic syndrome.